Successful Reversal of Hyperalgesia/Myoclonus Complex with Low-Dose Ketamine Infusion

Pain Practice

Volumn 12, Issue 2, 2012, Pages 154-158

  Forero, Mauricio ^a   Chan, Philip S L ^a   Restrepo Garces, Carlos E ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Intrathecal analgesia; Ketamine; Opioid tolerance; Opioid induced hyperalgesia

Indexed keywords

HYDROMORPHONE; KETAMINE; MORPHINE;

ARTICLE; BACKACHE; CASE REPORT; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; HUMAN; HYPERALGESIA; LOW BACK PAIN; LOW DRUG DOSE; MALE; MUSCLE SPASM; MYOCLONUS; OPIOID INDUCED HYPERALGESIA; PATIENT CONTROLLED ANALGESIA; PHYSICAL EXAMINATION; PHYSIOTHERAPY; SPINAL CORD STIMULATION;

EID: 84856583702     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00475.x     Document Type: Article

References (25)

1. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization dependent on N-methyl-D-aspartic acid receptor activation: implications for the treatment of post-injury pain hypersensitivity states. Pain. 1991;44:293-299.
2. Woolf CJ, Chong MS. Pre-emptive analgesia treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg. 1993;77:362-379.
3. Mercadante S, Arcuri E, Terelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage. 2000;20:144-149.
4. Lauretti GR, Lima I, Reis M, Prado W, Newton P. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology. 1999;90:1528-1533.
5. Backonja M, Arndt G, Gombar K, Check M, Zimmerman M. Response of chronic neuropathic pain syndromes to ketamine; a preliminary study. Pain. 1994;58:347-354.
6. Stannard CF, Porter GE. Ketamine hydrochloride in the treatment of phantom limb pain. Pain. 1993;54:227-230.
7. Bell RF. Ketamine for chronic non-cancer pain. Pain. 2009;141:210-214.
8. Singla A, Stojanovic MP, Chen L, Mao J. A differential diagnosis of hyperalgesia, toxicity, and withdrawal from intrathecal morphine infusion. Anesth Analg. 2007;105:1816-1819.
9. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24:479-496.
10. Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009;12:679-684.
11. Walker SM, Cousins MJ. Reduction in hyperalgesia and intrathecal morphine requierements by low-dose ketamine infusion. J Pain Symptom Manage. 1997;14:129-132.
12. Sator-Katzenschlager S, Deusch E, Maier P, Spacek A, Kress HG. The long-term antinociceptive effect of intrathecal S(+)-ketamine in a patient with established morphine tolerance. Anesth Analg. 2001;93:1032-1034.
13. Wilson RK, Weissman DE. Neurotoxicity effects of opioids: patient assessment #57. J Palliat Med. 2004;7:579-581.
14. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain. 1998;741:5-9.
15. Smith MT. Neurotoxicity effects of morphine and hydromorphone: evidence implicatiing the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000;27:524-528.
16. Bowsher D. Paradoxical pain: when the metabolites of morphine are in the wrong ratio. BMJ. 1993;306:473-474.
17. Saboory E, Derchansky M, Ismaili M, et al. Mechanisms of morphine enhancement of spontaneous seizure activity. Anesth Analg. 2007;105:1729-1735.
18. Kolesnikov Y, Jain S, Wilson R, Pasternak GW. Blockade of morphine-induced hindlimb myoclonic seizures in mice by ketamine. Pharmacol Biochem Behav. 1997;56:423-425.
19. Hemstapat K, Monteith GR, Smith D, Smith MT. Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-d-aspartic acid receptors: mechanistic studies in embryonic cultured hippocampal neurones. Anesth Analg. 2003;97:494-505.
20. Sjogren P, Jonsson T, Jensen NH, Drenck NE, Jensen TS. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain. 1993;55:93-97.
21. Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Palliat Med. 2004;7:545-550.
22. Wallace M, Yaksh TL. Long-term spinal analgesic delivery: a review of the preclinical and clinical literature. Reg Anesth Pain Med. 2000;25:117-157.
23. Kloke M, Bingel U, Seeber S. Complications of spinal opiod therapy: myoclonus, spastic muscle tone and spinal jerking. Support Care Cancer. 1994;2:249-252.
24. Deer T, Kramer ES, Hassenbusch SJ, et al. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert Panel. Neuromodulation. 2007;10:300-328.
25. Himmelseher S, Durieux ME. Ketamine for perioperative pain management. Anesthesiology. 2005;102:211-220.